To this end, Johnson et al. developed a serum-based tool (GALAD) to detect HCC based on objective measures including gender, age, and three serologic biomarkers (i.e., AFP, AFP-L3%, and PIVKA-II) (21). The gene discussed is AFP; the disease is hepatocellular carcinoma.